CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second...